SCHEMBL6700596

SCHEMBL6700596

O=C(O)CON=C1c2cc(S(=O)(=O)Nc3cccc(O)c3)ccc2-c2ccc(S(=O)(=O)Nc3cccc(O)c3)cc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.48
HSD17B2 P37059 2/20 0.48
PKM P14618 2/20 0.46
UQCRB P14927 1/20 0.46
MAPT P10636 3/20 0.45
POLB P06746 3/20 0.45
MEN1 O00255 2/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GAA P10253 1/20 0.41
STAT3 P40763 1/20 0.41
KDR P35968 4/20 0.41
AURKB Q96GD4 4/20 0.41
AURKA O14965 2/20 0.41
MAP4K4 O95819 1/20 0.40
PAK4 O96013 1/20 0.40
PIM1 P11309 1/20 0.40
LTK P29376 1/20 0.40
MAPK14 Q16539 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6702181 0.80 HSD17B2 (0.58) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6704050 0.80 AURKB (0.59) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6743069 0.80 HSD17B2 (0.52) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6704528 0.78 AURKB (0.59) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6703748 0.78 AURKB (0.59) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6703746 0.78 AURKB (0.59) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6703763 0.77 STAT3 (0.65) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6701816 0.77 HSD17B2 (0.54) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6699364 0.75 HSD17B2 (0.54) KMT2AHSD17B2PKMUQCRBMAPT
SCHEMBL6702498 0.74 STAT3 (0.69) KMT2AHSD17B2PKMUQCRBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US claimed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US claimed
US-6693136-B1 DISULFONAMIDE DERIVATIVES; PAIN, URINARY INCONTINENCE, BLADDER OVERACTIVITY ABBOTT LABORATORIES 2004-02-17 US disclosed
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS ABBVIE INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019042-A1 FLUORENES AND ANTHRACENES THAT INHIBIT P2X3 AND P2X2/3 CONTAINING RECEPTORS P2RX3, P2RX1, P2RX2 KMT2A 3944/4885HSD17B2 2678/4885PKM 2501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.